Albireo
is a Massachusetts-based biopharmaceutical firm that researches and develops novel bile acid modulators for the treatment of liver diseases... Read moreAlbireo
is a Massachusetts-based biopharmaceutical firm that researches and develops novel bile acid modulators for the treatment of liver diseases... Read more
News
Mar 03, 2023
Pharamceutical Technology
Albireo: Ipsen concludes purchase of Albireo Pharma
Feb 22, 2023
BioSpace
Albireo: Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
Feb 14, 2023
MarketScreener
Albireo: Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome
Feb 01, 2023
PR-Inside
Press Release: Albireo : ALBO STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE ...
Jan 24, 2023
MarketScreener
Albireo: ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO
Jan 24, 2023
Endpoints News
Albireo: Failed deal, bidding war paved the way for Ipsen's $952M rare disease buyout
Jan 13, 2023
PMLiVE
Albireo: Ipsen to acquire rare disease specialist Albireo in deal worth over $950m
Jan 11, 2023
LaingBuisson
Albireo: France: Ipsen bolstering Rare Disease portfolio with Albireo acquisition
Jan 09, 2023
Seeking Alpha
Albireo: Albireo stock jumps 85% as Ipsen set to acquire it for ~$952M
Jan 09, 2023
Citybizlist
Albireo: Ipsen to Acquire Albireo
Albireo Competitors
1
2
3
4
5
6
7